|
|
|
|
Immunocore Holdings Plc (NASDAQ: IMCR) |
|
Price: $29.6100
$0.29 
0.989%
|
| Day's High:
| $30
| Week Perf:
| -2.69 %
|
| Day's Low: |
$ 29.07 |
30 Day Perf: |
1.37 % |
| Volume (M): |
120 |
52 Wk High: |
$ 66.00 |
| Volume (M$): |
$ 3,547 |
52 Wk Avg: |
$37.48 |
| Open: |
$30.00 |
52 Wk Low: |
$27.19 |
|
|
| Market Capitalization (Millions $) |
1,483 |
| Shares
Outstanding (Millions) |
50 |
| Employees |
285 |
| Revenues (TTM) (Millions $) |
310 |
| Net Income (TTM) (Millions $) |
-51 |
| Cash Flow (TTM) (Millions $) |
15 |
| Capital Exp. (TTM) (Millions $) |
5 |
Immunocore Holdings Plc
Company Address: 92 Park Drive Abingdon, Oxfordshire 0
Company Phone Number: 438600 Stock Exchange / Ticker: NASDAQ IMCR
|
|
|
|
|
|
|
| Stock Performances by Major Competitors |
|
|
|
| Clinical Study
Published Mon, Dec 30 2024 2:24 AM UTC
Uveal melanoma (UM) is the most common primary intraocular malignancy, characterized by its aggressive nature and propensity for metastasis. Annually, approximately 1,500 to 2,500 new cases are diagnosed in the United States alone. Despite advances in local therapies, a significant number of patients will develop metastatic disease, warranting the need for effective adjuvant...
|
| Clinical Study
Published Sun, Dec 29 2024 2:59 PM UTC
In the fast-paced world of biopharmaceutical innovation, Immunocore Holdings Plc continues to forge ahead with promising research endeavors, despite facing formidable competition on multiple fronts. A notable development for the company involves the recent announcement of initiating the Phase 1/2 trial of IMC-R117C a novel therapeutic candidate targeting the PIWIL1 protein ...
|
| Announcement
Published Tue, Dec 3 2024 6:00 AM UTC
Immunocore Holdings Plc (NASDAQ: IMCR) has announced a significant milestone in cancer treatment as it has finalized a reimbursement agreement in England for its innovative therapy, KIMMTRAK, aimed at HLA-A 02:01-positive adults suffering from unresectable or metastatic uveal melanoma. This landmark decision is expected to enhance patient access to a vital therapy that has s...
|
| Clinical Study
Published Sat, Sep 14 2024 7:00 AM UTC
Immunocore Holdings Plc has marked a significant milestone in the realm of cancer therapies, as the company recently presented encouraging Phase 1 data on brenetafusp, a novel ImmTAC (Immune Mobilizing Monoclonal T cell receptors Against Cancer) bispecific targeting the cancer/testis antigen PRAME (Preferentially Expressed Antigen in Melanoma). This development comes at a cr...
|
| Per Share |
Current |
| Earnings (TTM) |
-1.02 $ |
| Revenues (TTM) |
6.19 $
|
| Cash Flow (TTM) |
0.3 $ |
| Cash |
16.38 $
|
| Book Value |
7.2 $
|
| Dividend (TTM) |
0 $ |
|
|
| Per Share |
|
| Earnings (TTM) |
-1.02 $
|
| Revenues (TTM) |
6.19 $ |
| Cash Flow (TTM) |
0.3 $ |
| Cash |
16.38 $
|
| Book Value |
7.2 $ |
| Dividend (TTM) |
0 $ |
|
|
|
|
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.
Copyright © 2025 CSIMarket, Inc. All rights
reserved.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
